x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012022
| Product Information | |
|---|---|
| Clonality | Monoclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB, IP, IF |
| Product Description | Monoclonal antibody is produced by immunizing animals with recombinant protein specific to the amino terminus of human FIS1 protein. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | FIS1 |
| UniProt No. | Q9Y3D6 |
| Gene ID | 51024 |
| Gene Description | Changes in mitochondrial dynamics regulated by environmental cues affect mitochondrial size and shape and have been shown to dramatically impact mitochondrial metabolism, apoptosis, and autophagy. Mitochondrial fusion and fission are dynamically controlled by several interacting proteins. Mitochondrial fission is controlled by the GTPase DRP1 which is recruited to the mitochondria by FIS1 and MFF. FIS1 is localized to the mitochondrial outer membrane and overexpression induces fission and leads to apoptosis. Decreased expression of FIS1 leads to mitochondrial elongation and triggers cellular senescence. Elevated expression of FIS1 can also promote autophagy. Studies also found that FIS1 interacts with the autophagy initiation protein STX17 and that depletion of FIS1 leads to an increase in mitochondrial localized STX17 and mitophagy. Expression of FIS1 has been associated with neurodegeneration and disease, including cancer. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at +4 °C short term (1-2 weeks). Store at -20 °C long term. |
| Storage Buffer | Constituent: 100% PBS |
Ace Therapeutics has a team of wellknown experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
